1. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers 
Christos Chouaid, MD, PhD, Laura Luciani, PharmD, MSc, Katell LeLay, MSc, Pascal Do, MD, Jaafar Bennouna, MD, PhD, Maurice Perol, MD, PhD, Denis Moro-Sibilot, MD, PhD, Alain Vergnenègre, MD, PhD, Gérard de Pouvourville, PhD 
Journal of Thoracic Oncology 
Volume 12, Issue 10, Pages (October 2017)
DOI: /j.jtho
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1 Model outline. PF, progression-free; PD, progressive disease.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
First-line afatinib versus gefitinib probabilistic sensitivity analysis scatterplots of incremental costs versus incremental quality-adjusted life-years (QALYs). All common EGFR mutations (A) and del19 (B) and L858R subgroups (C).
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

4. Figure 3
Acceptability curves of afatinib versus gefitinib. ITT, intention to treat.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions